SETD2 and chronic myelogenous leukemia, BCR-ABL1 positive: Studies have shown that SETD2 plays a tumor suppressor role in chronic myeloid leukemia (CML), and SETD2 loss significantly promotes imatinib resistance and leukemia stem cell enrichment in CML cells.